Q3 2021 13F Holders as of 30 Sep 2021
-
Type / Class
-
Equity / Common Stock - $0.001 par value
-
Shares outstanding
-
128M
-
Number of holders
-
52
-
Total 13F shares, excl. options
-
34.4M
-
Shares change
-
+34.4M
-
Total reported value, excl. options
-
$744M
-
Value change
-
+$744M
-
Number of buys
-
52
-
Price
-
$21.41
Significant Holders of Cytek Biosciences, Inc. - Common Stock - $0.001 par value (CTKB) as of Q3 2021
52 filings reported holding CTKB - Cytek Biosciences, Inc. - Common Stock - $0.001 par value as of Q3 2021.
Cytek Biosciences, Inc. - Common Stock - $0.001 par value (CTKB) has 52 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 34.4M shares
of 128M outstanding shares and own 26.85% of the company stock.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (9.61M shares), HHLR ADVISORS, LTD. (8.76M shares), FIL Ltd (2.67M shares), FMR LLC (2.67M shares), Miura Global Management, LLC (2.12M shares), ORBIMED ADVISORS LLC (1.92M shares), BlackRock Inc. (1.85M shares), VANGUARD GROUP INC (1.2M shares), Octagon Capital Advisors LP (500K shares), and PURA VIDA INVESTMENTS, LLC (444K shares).
This table shows the top 52 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.